Genetic Architecture of Alzheimer’s disease Proteinopathies
阿尔茨海默病的遗传结构 蛋白质病
基本信息
- 批准号:10581599
- 负责人:
- 金额:$ 189.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-15 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffectAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer&aposs disease pathologyAlzheimer&aposs disease riskAmyloidAmyloid beta-42Amyloid beta-ProteinApolipoprotein EAutomobile DrivingAutopsyBioinformaticsBiologicalBiological MarkersBrainBrain DiseasesCell modelCell physiologyCerebrospinal FluidClinicalDataData SetDementiaDiseaseEtiologyGene ExpressionGenesGeneticGenetic VariationGenetic studyGenome ScanGenomicsGenotypeGoalsImpaired cognitionIn VitroIndividualInterventionMagnetic Resonance ImagingMeasuresMediationMendelian randomizationMethodsMyeloid CellsNational Institute on AgingNatureNerve DegenerationNeurofibrillary TanglesNeuronal InjuryOutcomePathogenesisPathologicPathologic ProcessesPathologyPathway interactionsPersonsPhasePhenotypePlasmaPositron-Emission TomographyPreventive measureProxyPublic HealthQuantitative Trait LociRecommendationResearchResearch SubjectsRiskRoleSamplingSenile PlaquesSignal TransductionSymptomsTestingVariantabeta depositionamyloid pathologybiomarker validationclinical diagnosiscomorbiditydiagnostic valueeffective therapyendophenotypeexperimental studyextracellularfluorodeoxyglucose positron emission tomographyfollow-upgenetic architecturegenetic associationgenetic informationgenetic variantgenome sequencinggenome wide association studyimprovedinterestneuroimagingneuropathologynovelpersonalized medicinepolygenic risk scorepopulation basedpre-clinicalpreventrare varianttau Proteinstau-1whole genome
项目摘要
Project Summary/Abstract
In order to enhance and focus research on Alzheimer's disease (AD)-specific proteinopathies, the 2018
research framework proposed by the National Institute on Aging and Alzheimer's Association (NIA-AA)
recommends that AD be defined by its specific biological signatures that can be documented at autopsy or in
living people by biomarkers rather than by its non-specific neurodegenerative and clinical syndromic features.
Of the three proposed biomarkers by the NIA-AA research framework in living people (amyloid-beta (Aβ),
pathologic tau and neurodegeneration), only the two AD-specific proteinopathies (Aβ and pathologic tau) are
considered obligatory for the biological definition of AD, while neurodegeneration, although contribute to
cognitive impairment and is part of the fully manifested disease, can also occur in other brain disorders and
thus is not specific to AD. The purpose of this harmonized biological definition of AD in living people that
includes the preclinical phase is to distinguish AD from other types of brain disorders and dementia, to
accelerate and focus research on AD-specific proteinopathies that manifest decades before the clinical
manifestation of first symptoms of AD, to enhance better understanding in the underlying mechanisms of AD
clinical expression, and to use (and discover) targeted disease modifying interventions that can prevent or
delay the onset of AD symptoms.
Our ongoing and long-term research interest coincides well with the NIA-AA research framework in living
people where we have already performed genome-wide association studies (GWAS) on CSF Aβ42/tau levels
and Aβ deposition in the brain measured by amyloid-PET and identified known and novel associations in the
APOE and non-APOE regions. However, the identified signals do not explain all of the phenotypic variation in
the two AD-specific proteinopathies or endophenotypes. Here we propose a collaborative study between
leading experts in the field to extend our ongoing efforts to delineate the complete genetic basis of the two AD-
specific proteinopathies (Aβ and pathologic tau) by whole genome sequencing (WGS) using well-characterized
and large amyloid-PET and CSF Aβ42/tau datasets with clinical outcomes of dementia followed by testing the
effects of identified significant variants on downstream neurodegeneration markers, and performing extensive
bioinformatics and functional studies. The primary objective of this application is to perform and analyze WGS
in adequately powered large discovery samples with well-characterized Aβ and tau data along with clinical
outcomes of dementia to identify putative functional variants associated with Aβ and tau pathologies followed
by replications in independent and large samples with Aβ and tau data (Aims 1-2). We will integrate genetic
information to create polygenic risk scores in order to predict Aβ and tau pathologies and will also examine the
role of AD pathology-associated variants with downstream neurodegeneration, neuropathologies that coexist
with AD and the risk and age-at-onset of AD (Aim3). Finally, we will functionally characterize genetic
association using bioinformatics, causality tests and in vitro experiments to understand their roles in affecting
gene expression as being expression quantitative traits loci, affecting intracellular and extracellular APP/Aβ
and tau levels, and in myeloid cell function. The successful completion of this study will help to identify novel
AD-related genes and pathways, and to uncover underlying possible mechanisms for AD.
项目摘要/摘要
为了增强和重点研究阿尔茨海默氏病(AD)特定蛋白质,2018年
美国国家老化研究所和阿尔茨海默氏症协会(NIA-AA)提出的研究框架
建议通过其特定的生物学特征来定义广告,该特定的生物学特征可以记录在尸检时或IN
生物标志物而不是其非特异性神经退行性和临床综合征特征。
NIA-AA研究框架的三种拟议的生物标志物(淀粉样蛋白β(Aβ),
病理性的tau和神经退行性),仅两种AD特异性蛋白质病(Aβ和病理tau)是
被认为是AD的生物学定义的强制性,而神经退行性则有助于
认知障碍,是完全明显疾病的一部分,也可能发生在其他脑部疾病中
因此不是特定于AD的。这个在活人中对广告的统一生物学定义的目的
包括临床前阶段是将AD与其他类型的脑疾病和痴呆区分开,
加速并重点研究广告特异性的蛋白质病,这些蛋白质疾病在临床之前几十年表现出来
AD的首次症状的表现,以增强在AD的潜在机制中更好地理解
临床表达,并使用(并发现)有针对性的疾病修改可以预防或
延迟广告符号的发作。
我们正在进行的长期研究兴趣与NIA-AA生活框架相吻合
我们已经在CSFAβ42/TAU水平上进行了全基因组关联研究(GWAS)的人
通过淀粉样-PET测量的大脑中的Aβ沉积,并确定了已知和新颖的关联
APOE和非APOE地区。但是,已确定的信号并不能解释所有表型变化
两种AD特异性蛋白质病或内表型。在这里,我们提出了一项合作研究
该领域的领先专家扩大了我们持续的努力来描述这两个广告的完整遗传基础
通过良好的特征化,整个基因组测序(WGS)的特定蛋白质病(Aβ和病理TAU)
以及具有痴呆症的临床结局,然后测试大型淀粉样蛋白PET和CSFAβ42/TAU数据集
鉴定出明显变体对下游神经变性标记的影响,并进行广泛的影响
生物信息学和功能研究。该应用的主要目的是执行和分析WGS
在充分动力的大型发现样品中,具有良好的Aβ和TAU数据以及临床
痴呆症的结果以识别与Aβ和TAU病理相关的推定功能变异
通过在具有Aβ和TAU数据的独立和大型样品中复制(目标1-2)。我们将整合遗传
信息以创建多基因风险评分以预测Aβ和TAU病理,还将检查
与下游神经退行性变体相关变体的作用,神经病理学
AD以及AD的风险和年龄(AIM3)。最后,我们将在功能上表征通用
使用生物信息学,休闲测试和体外实验的关联,以了解其影响
基因表达是表达定量性状基因座,影响细胞内和细胞外应用/Aβ
和tau水平,以及髓样细胞功能。这项研究的成功完成将有助于确定新颖
与广告相关的基因和途径,并发现AD的潜在机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carlos Cruchaga其他文献
Carlos Cruchaga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carlos Cruchaga', 18)}}的其他基金
Identification and Characterization of Cell-Specific Transposable Elements Implicated on Alzheimer Disease and Healthy Aging
与阿尔茨海默病和健康衰老相关的细胞特异性转座元件的鉴定和表征
- 批准号:
10518934 - 财政年份:2022
- 资助金额:
$ 189.59万 - 项目类别:
Multimodal Characterization of the Role of Circular RNAs in Alzheimer's Disease
环状 RNA 在阿尔茨海默病中作用的多模式表征
- 批准号:
10446362 - 财政年份:2022
- 资助金额:
$ 189.59万 - 项目类别:
Identification and Characterization of Cell-Specific Transposable Elements Implicated on Alzheimer Disease and Healthy Aging
与阿尔茨海默病和健康衰老相关的细胞特异性转座元件的鉴定和表征
- 批准号:
10677894 - 财政年份:2022
- 资助金额:
$ 189.59万 - 项目类别:
Genetic Architecture of Alzheimer’s disease Proteinopathies
阿尔茨海默病的遗传结构 蛋白质病
- 批准号:
9995650 - 财政年份:2021
- 资助金额:
$ 189.59万 - 项目类别:
Genetic Architecture of Alzheimer’s disease Proteinopathies
阿尔茨海默病的遗传结构 蛋白质病
- 批准号:
10391426 - 财政年份:2021
- 资助金额:
$ 189.59万 - 项目类别:
THE GENETICS AND MULTI-OMICS SPECIMENS CORE (GMSC)
遗传学和多组学样本核心 (GMSC)
- 批准号:
10283067 - 财政年份:2021
- 资助金额:
$ 189.59万 - 项目类别:
THE GENETICS AND MULTI-OMICS SPECIMENS CORE (GMSC)
遗传学和多组学样本核心 (GMSC)
- 批准号:
10673899 - 财政年份:2021
- 资助金额:
$ 189.59万 - 项目类别:
Brain Single-nuclei and iPS-derived cells transcriptomic analysis to define the contribution of neuronal and glial pathw
脑单核和 iPS 衍生细胞转录组分析以确定神经元和神经胶质通路的贡献
- 批准号:
10302162 - 财政年份:2021
- 资助金额:
$ 189.59万 - 项目类别:
Genetic Architecture of Alzheimer’s disease Proteinopathies
阿尔茨海默病的遗传结构 蛋白质病
- 批准号:
10532581 - 财政年份:2021
- 资助金额:
$ 189.59万 - 项目类别:
相似国自然基金
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
- 批准号:82373667
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
恒星模型中氧元素丰度的变化对大样本F、G、K矮星年龄测定的影响
- 批准号:12303035
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于年龄和空间的非随机混合对性传播感染影响的建模与研究
- 批准号:12301629
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
- 批准号:82304205
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
中国东部地区大气颗粒物的年龄分布特征及其影响因素的模拟研究
- 批准号:42305193
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Causes and Downstream Effects of 14-3-3 Phosphorylation in Synucleinopathies
突触核蛋白病中 14-3-3 磷酸化的原因和下游影响
- 批准号:
10606132 - 财政年份:2024
- 资助金额:
$ 189.59万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 189.59万 - 项目类别:
Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers Disease
线粒体脂质组动力学及其与 APOE 亚型的相互作用对脑衰老和阿尔茨海默病的影响
- 批准号:
10645610 - 财政年份:2023
- 资助金额:
$ 189.59万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 189.59万 - 项目类别:
Cerebrovascular mitochondria as mediators of neuroinflammation in Alzheimer's Disease
脑血管线粒体作为阿尔茨海默病神经炎症的介质
- 批准号:
10723580 - 财政年份:2023
- 资助金额:
$ 189.59万 - 项目类别: